Free Trial

Benitec Biopharma (NASDAQ:BNTC) Stock Passes Below 50 Day Moving Average - Here's Why

Benitec Biopharma logo with Medical background

Shares of Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $14.27 and traded as low as $12.47. Benitec Biopharma shares last traded at $13.14, with a volume of 74,946 shares trading hands.

Wall Street Analysts Forecast Growth

BNTC has been the topic of a number of recent research reports. JMP Securities restated a "market outperform" rating and set a $20.00 price target on shares of Benitec Biopharma in a research note on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $28.00 target price on shares of Benitec Biopharma in a research note on Monday, May 19th. Finally, TD Cowen assumed coverage on shares of Benitec Biopharma in a research note on Monday. They issued a "buy" rating on the stock. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $23.83.

Check Out Our Latest Stock Report on BNTC

Benitec Biopharma Stock Down 6.4%

The stock's fifty day moving average price is $14.25 and its 200 day moving average price is $12.95. The stock has a market cap of $331.28 million, a P/E ratio of -8.36 and a beta of 0.37. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. As a group, research analysts forecast that Benitec Biopharma Limited will post -1.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Benitec Biopharma

A number of institutional investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC increased its holdings in shares of Benitec Biopharma by 1.5% in the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock worth $113,165,000 after buying an additional 130,956 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after buying an additional 2,142,643 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Benitec Biopharma by 198.5% in the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock worth $33,268,000 after buying an additional 1,739,904 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Benitec Biopharma by 134.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock worth $24,913,000 after buying an additional 1,131,129 shares during the last quarter. Finally, Infinitum Asset Management LLC grew its holdings in shares of Benitec Biopharma by 435.7% during the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock valued at $14,636,000 after purchasing an additional 915,000 shares during the last quarter. Institutional investors own 52.19% of the company's stock.

Benitec Biopharma Company Profile

(Get Free Report)

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

Featured Stories

Should You Invest $1,000 in Benitec Biopharma Right Now?

Before you consider Benitec Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.

While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines